Oncomine™ Tumor Mutation Load Assay, Chef-ready library preparation

The Oncomine Tumor Mutation Load Assay is a targeted next-generation sequencing (NGS) assay that provides an assessment of tumor mutation load and mutation signatures in a simple workflow. The assay provides reagents for library construction from two pools of multiplex PCR primers for preparation of amplicon libraries from formalin-fixed paraffin-embedded (FFPE) tumor samples without the need for a matched normal sample, using 10 ng of DNA per primer pool. This assay is designed to facilitate successful selection and identification of samples most likely to derive responses in cancer immunotherapy research.

Features:
• Enables accurate quantitation of somatic mutations to assess tumor mutation load
• Single tumor sample workflow reduces the need for a matched normal sample
• Efficient amplification from challenging samples with AmpliSeq technology
• Streamlined analysis with feature-rich visualization
• Efficient multiplexing of up to eight samples per Ion 540 Chip on the Ion S5 Systems

The Oncomine Tumor Mutation Load Assay, Chef-Ready Library Preparation, includes panel primers and reagents for automated library construction and normalization sufficient for 32 samples. This version of the assay is for automated library preparation using the Ion Chef System. For manual library preparation, please see Cat. No. A37909.

From sample to answer
The Oncomine Tumor Mutation Load Assay comes with optimized informatics and visualization software that provides a sample-to-answer solution. Run metrics can be assessed using a Torrent Suite plugin. The Ion Reporter analysis workflow utilizes a custom variant calling and germline variant filtering algorithm to accurately estimate somatic variants in cancer research samples. A detailed report is provided that includes the normalized mutation load (mutations/MB) and mutation signatures of the somatic variants, including percentage of mutations consistent with UV damage, tobacco smoke damage, de-amination, and specific substitutions.

Learn more about Oncomine Oncology ›